Gema Durán
A5013762326- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- Retinal Diseases and Treatments
- Lung Cancer Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Brain Metastases and Treatment
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Pancreatitis Pathology and Treatment
- Ocular Oncology and Treatments
- Melanoma and MAPK Pathways
- Sarcoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Neuroendocrine Tumor Research Advances
- Glaucoma and retinal disorders
- Advanced Breast Cancer Therapies
Hospital Clínico Universitario Virgen de la Victoria
2020-2022
Instituto de Investigación Biomédica de Málaga
2020-2022
Hospital Regional Universitario de Málaga
2006-2014
Chemotherapy plus anti-EGFR is standard first-line therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC), but biomarkers of early response are clinically needed. We aimed to define the utility ctDNA assess patients with mCRC receiving therapy.Prospective multicentric study tissue wt treated chemotherapy cetuximab undergoing sequential liquid biopsies. Baseline and (C3) were analyzed by NGS. Trunk mutations assessed as surrogate marker total tumor burden. RAS/BRAF/MEK/EGFR-ECD...
Dihydropyrimidine dehydrogenase (DPD) is a metabolic enzyme that crucial in 5-fluorouracil (5-FU) degradation. A deficiency it associated with the occurrence of adverse events following fluoropyrimidine-based therapies. We describe case toxicity grade 5 after administration capecitabine and oxaliplatin patient stage III colorectal cancer DPD congenital deficiency, which was identified later. Several polymorphisms have been global 5-FU; however, genetic tests are low sensitivity therefore...
Presentamos la descripción del caso clínico de un paciente 65 años con carcinoma pulmón no microcítico (CPNCP) avanzado que debuta una alteración campo visual derecho, sin otros síntomas, diagnosticándose en exploración oftalmoscópica metástasis coroidea, realización angiografía fluresceínica para diferenciarlo hemorragia o hemangioma.Este destaca por el área infrecuente y
<div>AbstractPurpose:<p>Chemotherapy plus anti-EGFR is standard first-line therapy in <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC), but biomarkers of early response are clinically needed. We aimed to define the utility ctDNA assess patients with mCRC receiving therapy.</p>Experimental Design:<p>Prospective multicentric study tissue wt treated chemotherapy cetuximab undergoing sequential liquid biopsies. Baseline and (C3) were analyzed by...
<div>AbstractPurpose:<p>Chemotherapy plus anti-EGFR is standard first-line therapy in <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC), but biomarkers of early response are clinically needed. We aimed to define the utility ctDNA assess patients with mCRC receiving therapy.</p>Experimental Design:<p>Prospective multicentric study tissue wt treated chemotherapy cetuximab undergoing sequential liquid biopsies. Baseline and (C3) were analyzed by...
Purpouse:The activity of vinorelbine (VRL) as single agent in treatment-naïve inoperable non small cell cancer (NSCLC) patients (pts) has been assessed several published studies.Oral and intravenous formulation have a linearity VRL pharmacokinetics with both routes administration.This is study oral first line advanced NSCLC elderly pts. Patients methods:A total 12 chemonaive pts ≥ 70 years were recruited from October 2005 through to June 2006.Principal inclusion criteria included...